GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Enterprise Value

GeneDx Holdings (GeneDx Holdings) Enterprise Value : $574.5 Mil (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, GeneDx Holdings's Enterprise Value is $574.5 Mil. GeneDx Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-126.3 Mil. Therefore, GeneDx Holdings's EV-to-EBIT ratio for today is -4.55.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, GeneDx Holdings's Enterprise Value is $574.5 Mil. GeneDx Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-96.0 Mil. Therefore, GeneDx Holdings's EV-to-EBITDA ratio for today is -5.98.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, GeneDx Holdings's Enterprise Value is $574.5 Mil. GeneDx Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $221.8 Mil. Therefore, GeneDx Holdings's EV-to-Revenue ratio for today is 2.59.


GeneDx Holdings Enterprise Value Historical Data

The historical data trend for GeneDx Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings Enterprise Value Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 696.06 55.69 61.06

GeneDx Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 164.85 72.23 53.71 61.06 243.95

Competitive Comparison of GeneDx Holdings's Enterprise Value

For the Health Information Services subindustry, GeneDx Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneDx Holdings's Enterprise Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GeneDx Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Enterprise Value falls into.



GeneDx Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

GeneDx Holdings's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

GeneDx Holdings's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneDx Holdings  (NAS:WGS) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

GeneDx Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=574.497/-126.341
=-4.55

GeneDx Holdings's current Enterprise Value is $574.5 Mil.
GeneDx Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.3 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

GeneDx Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=574.497/-95.995
=-5.98

GeneDx Holdings's current Enterprise Value is $574.5 Mil.
GeneDx Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-96.0 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

GeneDx Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=574.497/221.849
=2.59

GeneDx Holdings's current Enterprise Value is $574.5 Mil.
GeneDx Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $221.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneDx Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneDx Holdings (GeneDx Holdings) Business Description

Traded in Other Exchanges
N/A
Address
333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.
Executives
Kareem Saad officer: Chief Business Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland director, officer: Chief Executive Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley officer: Chief Financial Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister director, 10 percent owner C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White officer: Chief People Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp director, 10 percent owner C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp director, 10 percent owner 667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137